

1 Robert V. Prongay (SBN 270796)
rprongay@glancylaw.com
2 Charles Linehan (SBN 307439)
clinehan@glancylaw.com
3 Pavithra Rajesh (SBN 323055)
prajesh@glancylaw.com
4 GLANCY PRONGAY & MURRAY LLP
5 1925 Century Park East, Suite 2100
6 Los Angeles, California 90067
7 Telephone: (310) 201-9150
Facsimile: (310) 201-9160

8 *Attorneys for Plaintiff Joseph Fazio*

9
10 **UNITED STATES DISTRICT COURT**
11 **NORTHERN DISTRICT OF CALIFORNIA**

12 JOSEPH FAZIO, Individually and on Behalf
13 of All Others Similarly Situated,

14 Plaintiff,

15 v.

16 EARGO, INC., CHRISTIAN GORMSEN, and
17 ADAM LAPONIS,

18 Defendant.

Case No.

**CLASS ACTION COMPLAINT FOR
VIOLATIONS OF THE FEDERAL
SECURITIES LAWS**

DEMAND FOR JURY TRIAL

1 Plaintiff Joseph Fazio (“Plaintiff”), individually and on behalf of all others similarly situated,
2 by and through his attorneys, alleges the following upon information and belief, except as to those
3 allegations concerning Plaintiff, which are alleged upon personal knowledge. Plaintiff’s information
4 and belief is based upon, among other things, his counsel’s investigation, which includes without
5 limitation: (a) review and analysis of regulatory filings made by Eargo, Inc. (“Eargo” or the
6 “Company”) with the United States (“U.S.”) Securities and Exchange Commission (“SEC”); (b)
7 review and analysis of press releases and media reports issued by and disseminated by Eargo; and
8 (c) review of other publicly available information concerning Eargo.

9 **NATURE OF THE ACTION AND OVERVIEW**

10 1. This is a class action on behalf of persons and entities that purchased or otherwise
11 acquired Eargo securities between February 25, 2021 and September 22, 2021, inclusive (the “Class
12 Period”). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934
13 (the “Exchange Act”).

14 2. Eargo is a medical device company. It claims that its hearing aids “are the first and
15 only virtually invisible, rechargeable, completely-in-canal, FDA-regulated, exempt Class I and
16 Class II devices for the treatment of hearing loss.”

17 3. On August 12, 2021, after the market closed, Eargo revealed that claims submitted
18 to the Company’s largest third-party payor, which accounted for 80% of Eargo’s accounts
19 receivable, had not been paid since March 1, 2021.

20 4. On this news, the Company’s share price fell \$8.00, or over 24%, to close at \$24.70
21 per share on August 13, 2021, on unusually heavy trading volume.

22 5. On September 22, 2021, after the market closed, Eargo revealed that “it is the target
23 of a criminal investigation by the U.S. Department of Justice (the ‘DOJ’) related to insurance
24 reimbursement claims the Company has submitted on behalf of customers covered by federal
25 employee health plans.” Moreover, the DOJ is the “principal contact related to the subject matter of
26 the [ongoing] audit” of Eargo by an insurance company that is the Company’s largest third-party
27 payor. As a result of the foregoing, Eargo withdrew its full year financial guidance.
28

1 6. On this news, the Company's share price fell \$14.81, or over 68%, to close at \$6.86
2 per share on September 23, 2021, on unusually heavy trading volume.

3 7. Throughout the Class Period, Defendants made materially false and/or misleading
4 statements, as well as failed to disclose material adverse facts about the Company's business,
5 operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Eargo had
6 improperly sought reimbursements from certain third-party payors; (2) that the foregoing was
7 reasonably likely to lead to regulatory scrutiny; (3) that, as a result and because the reimbursements
8 at issue involved the Company's largest third-party payor, Eargo's financial results would be
9 adversely impacted; and (4) that, as a result of the foregoing, Defendants' positive statements about
10 the Company's business, operations, and prospects were materially misleading and/or lacked a
11 reasonable basis.

12 8. As a result of Defendants' wrongful acts and omissions, and the precipitous decline
13 in the market value of the Company's securities, Plaintiff and other Class members have suffered
14 significant losses and damages.

15 **JURISDICTION AND VENUE**

16 9. The claims asserted herein arise under Sections 10(b) and 20(a) of the Exchange Act
17 (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder by the SEC (17 C.F.R. §
18 240.10b-5).

19 10. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C.
20 § 1331 and Section 27 of the Exchange Act (15 U.S.C. § 78aa).

21 11. Venue is proper in this Judicial District pursuant to 28 U.S.C. § 1391(b) and Section
22 27 of the Exchange Act (15 U.S.C. § 78aa(c)). Substantial acts in furtherance of the alleged fraud
23 or the effects of the fraud have occurred in this Judicial District. Many of the acts charged herein,
24 including the dissemination of materially false and/or misleading information, occurred in
25 substantial part in this Judicial District. In addition, the Company's principal executive offices are
26 located in this District.

27 12. In connection with the acts, transactions, and conduct alleged herein, Defendants
28 directly and indirectly used the means and instrumentalities of interstate commerce, including the

1 United States mail, interstate telephone communications, and the facilities of a national securities
2 exchange.

3 **PARTIES**

4 13. Plaintiff Joseph Fazio, as set forth in the accompanying certification, incorporated
5 by reference herein, purchased Eargo securities during the Class Period, and suffered damages as a
6 result of the federal securities law violations and false and/or misleading statements and/or material
7 omissions alleged herein.

8 14. Defendant Eargo is incorporated under the laws of Delaware with its principal
9 executive offices located in San Jose, California. Eargo's common stock trades on the NASDAQ
10 exchange under the symbol "EAR."

11 15. Defendant Christian Gormsen ("Gormsen") was the Company's Chief Executive
12 Officer ("CEO") at all relevant times.

13 16. Defendant Adam Laponis ("Laponis") was the Company's Chief Financial Officer
14 ("CFO") at all relevant times.

15 17. Defendants Gormsen and Laponis (collectively the "Individual Defendants"),
16 because of their positions with the Company, possessed the power and authority to control the
17 contents of the Company's reports to the SEC, press releases and presentations to securities analysts,
18 money and portfolio managers and institutional investors, i.e., the market. The Individual
19 Defendants were provided with copies of the Company's reports and press releases alleged herein
20 to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to
21 prevent their issuance or cause them to be corrected. Because of their positions and access to
22 material non-public information available to them, the Individual Defendants knew that the adverse
23 facts specified herein had not been disclosed to, and were being concealed from, the public, and that
24 the positive representations which were being made were then materially false and/or misleading.
25 The Individual Defendants are liable for the false statements pleaded herein.

1 **SUBSTANTIVE ALLEGATIONS**

2 **Background**

3 18. Eargo is a medical device company. It claims that its hearing aids “are the first and
4 only virtually invisible, rechargeable, completely-in-canal, FDA-regulated, exempt Class I and
5 Class II devices for the treatment of hearing loss.”

6 **Materially False and Misleading**

7 **Statements Issued During the Class Period**

8 19. The Class Period begins on February 25, 2021. On that day, Eargo announced its
9 fourth quarter and full year 2020 financial results in a press release that stated, in relevant part:

10 **Recent Highlights:**

- 11 • Net revenues of \$22.4 million in the fourth quarter and \$69.2 million for the
12 full year of 2020, representing 110.8% and 110.9% increases, respectively,
over the corresponding periods of 2019
- 13 • Gross systems shipped of 12,096 in the fourth quarter and 38,243 for the full
14 year of 2020, representing 67.7% and 67.8% increases, respectively, over the
corresponding periods of 2019
- 15 • Return accrual rate of 24.4% in the fourth quarter and 25.9% for the full year
16 of 2020, representing a 9.6 and 9.0 percentage point improvement,
respectively, over the corresponding periods of 2019
- 17 • Gross margin of 70.6% in the fourth quarter and 68.4% for the full year of
18 2020, representing a 15.4 and 16.6 percentage point improvement,
respectively, over the corresponding periods of 2019; non-GAAP gross
19 margin of 70.8% in the fourth quarter and 68.5% for the full year of 2020
representing a 15.5 and 16.6 percentage point improvement, respectively,
over the corresponding periods of 2019

20 * * *

21 **Full Year 2021 Financial Guidance**

- 22 • Net revenue of between \$87 million and \$93 million
- 23 • GAAP gross margin of between 68% and 71%
- 24 • Non-GAAP gross margin of between 70% and 72%

25 20. On March 16, 2021, Eargo filed its annual report on Form 10-K for the period ended
26 December 31, 2020 (the “2020 10-K”), affirming the previously reported financial results.
27 Regarding reimbursements from third-party payors, the report stated:
28

1 ***Changes in third-party coverage and reimbursement may impact our ability to***
2 ***grow and sell our products.***

3 Our products are primarily purchased on a cash-pay basis and currently only have
4 limited coverage by third-party payors. Third-party coverage and reimbursement
5 may increase for certain hearing aids but not our products, or could decrease for our
6 products, which could reduce our market share. The process for determining whether
7 a third-party payor will provide coverage for a product may be separate from the
8 process for establishing the reimbursement rate that such a payor will pay for the
9 product. A payor's decision to provide coverage for a product does not imply that an
10 adequate reimbursement rate will be approved. Further, one payor's determination
11 to provide coverage for a product does not assure that other payors will also provide
12 such coverage. Third-party coverage and reimbursement may never become
13 available to us at sufficient levels.

14 21. On May 12, 2021, Eargo announced its first quarter 2021 financial results in a press
15 release that stated, in relevant part:

16 **Recent Highlights:**

- 17 • Net revenues of \$22.0 million, up 74.0% year-over-year
- 18 • Gross systems shipped of 11,704, up 66.5% year-over-year
- 19 • Return accrual rate of 23.2%, a 4.4 percentage point improvement year-over-year
- 20 • GAAP gross margin of 71.4%, up 8.2 percentage points year-over-year; non-GAAP gross margin of 72.2%, up 9.0 percentage points year-over-year

21 * * *

22 **Full Year 2021 Financial Guidance**

- 23 • Increasing net revenue guidance from between \$87 million and \$93 million to between \$89 million and \$93 million
- 24 • Reiterating GAAP gross margin guidance of between 68% and 71%
- 25 • Reiterating non-GAAP gross margin of between 70% and 72%

26 22. On May 13, 2021, Eargo filed its quarterly report on Form 10-Q for the period ended
27 March 31, 2021 (the "1Q21 10-Q"), affirming the previously reported financial results. Regarding
28 third-party payors, it stated, in relevant part:

A significant portion of our revenue is dependent upon reimbursement from third-party payors. Any material changes to third-party coverage or reimbursement could significantly impact our business and our ability to grow and sell our products.

A significant portion of our revenue depends on payments from third-party payors that we submit claims to on behalf of our customers. If there are decreases in hearing

1 aid benefits offered under these plans, our ability to seek third-party reimbursement
2 could be reduced. Decreases in hearing benefits could lead to changes in the amount
3 these plans will pay for hearing aids, the types of providers these plans allow their
4 members to see for hearing aids, or how often the plans will pay for hearing aids. If
5 we fail to maintain access to existing levels of coverage and reimbursement for our
6 products, our business and operating results could be adversely affected.

7 We currently submit claims on behalf of customers to a concentrated number of third-
8 party payors under certain benefit plans. Additionally, third-party payors periodically
9 conduct pre- and post-payment reviews, including audits of previously submitted
10 claims, and we are currently experiencing and may experience such reviews and
11 audits of claims in the future. **For example, we are currently subject to a routine
12 audit with our largest third-party payor, who accounted for approximately 57% of
13 the Company's gross accounts receivable as of March 31, 2021.** Such reviews and
14 audits of our claims have resulted and could in the future result in significant delays
15 in payment, and could result in material recoupments of previous claims paid or
16 denials of pending or future claims, which could impact our ability to recognize
17 revenue, reduce our net sales and profitability, or result in the loss of our ability to
18 submit claims to certain third-party payors for payment.

19 (Second emphasis added.)

20 23. The above statements identified in ¶¶ 19-22 were materially false and/or misleading,
21 and failed to disclose material adverse facts about the Company's business, operations, and
22 prospects. Specifically, Defendants failed to disclose to investors: (1) that Eargo had improperly
23 sought reimbursements from certain third-party payors; (2) that the foregoing was reasonably likely
24 to lead to regulatory scrutiny; (3) that, as a result and because the reimbursements at issue involved
25 the Company's largest third-party payor, Eargo's financial results would be adversely impacted; and
26 (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business,
27 operations, and prospects were materially misleading and/or lacked a reasonable basis.

28 24. The truth began to emerge on August 12, 2021, after the market closed, when Eargo
revealed that claims submitted to the Company's largest third-party payor had not been paid since
March 1, 2021. In a press release announcing its second quarter 2021 financial results, Eargo stated,
in relevant part:

Accounts receivable, net was \$15.4 million as of June 30, 2021. The increase in
accounts receivable from March 31, 2021 was primarily due to a claims audit by an
insurance company that is our largest third-party payor, who accounted for
approximately 80% of our gross accounts receivable as of June 30, 2021. **During the
audit, claims since March 1, 2021 have not been paid.** The Company is in active
discussions with the payor and continues to work toward conclusion of the audit.

1 **Full Year 2021 Financial Guidance**

- 2 • Increasing net revenue guidance from between \$89 million and \$93 million
3 to between \$93 million and \$96 million
- 4 • Reiterating GAAP gross margin guidance of between 68% and 71%
- 5 • Reiterating non-GAAP gross margin of between 70% and 72%

6 25. Moreover, the same day, Eargo filed its quarterly report on Form 10-Q for the period
7 ended June 30, 2021 (the “2Q21 10-Q”), affirming the previously reported financial results.

8 Regarding third-party payors, the report stated:

9 *A significant portion of our revenue is dependent upon reimbursement from third-*
10 *party payors. Any material changes to third-party coverage or reimbursement or*
11 *adverse outcomes of third-party payor audits could significantly impact our*
12 *business and our ability to grow and sell our products.*

13 A significant portion of our revenue depends on payments from third-party payors
14 that we submit claims to on behalf of our customers. If there are decreases in hearing
15 aid benefits offered under these plans, our ability to seek third-party reimbursement
16 could be reduced. Decreases in hearing benefits could lead to changes in the amount
17 these plans will pay for hearing aids, the types of providers these plans allow their
18 members to see for hearing aids, or how often the plans will pay for hearing aids. If
19 we fail to maintain access to existing levels of coverage and reimbursement for our
20 products, our business and operating results could be adversely affected.

21 We currently submit claims on behalf of customers to a concentrated number of third-
22 party payors under certain benefit plans. Additionally, third-party payors periodically
23 conduct pre- and post-payment reviews, including audits of previously submitted
24 claims, and we are currently experiencing and may experience such reviews and
25 audits of claims in the future. *For example, we are currently subject to a claims*
26 *audit with our largest third-party payor, who accounted for approximately 80% of*
27 *our gross accounts receivable as of June 30, 2021, during which claims submitted*
28 *since March 1, 2021 have not been paid. Reimbursement claims submitted to*
another insurance company are also currently undergoing an audit, and to date
claims from this insurance company have been processed and approved consistent
with normal business practices during the audit. In addition to the risk that the
insurance companies may deny the claims subject to the current audits, and we have
received some denials to date, it is possible that they may seek recoupments of
previous claims paid and deny any future claims. While we believe the claims
submitted are valid and reimbursable with these insurance companies, and there
exist processes for appeal and, if necessary, corrective action, an unfavorable
outcome of the ongoing audits could have a material adverse effect on our future
financial results, including our revenue recognition, sales return rate and bad debt
reserve. We are unable to provide assurances regarding the outcome of these audits.
Such reviews and audits of our claims have resulted and could in the future result in
significant delays in payment, and could result in material recoupments of previous
claims paid or denials of pending or future claims, which could impact our ability to
recognize revenue, reduce our net sales and profitability, or result in the loss of our
ability to submit claims to certain third-party payors for payment.

(Second and third emphases added.)

1 26. On this news, the Company’s share price fell \$8.00, or over 24%, to close at \$24.70
2 per share on August 13, 2021, on unusually heavy trading volume.

3 27. The 2Q21 10-Q also stated that the Company may be subject to penalties for
4 violations of certain healthcare laws and regulations. Specifically, it stated:

5 *If we fail to comply with U.S. or foreign federal and state healthcare regulatory*
6 *laws, we could be subject to penalties, including, but not limited to, administrative,*
7 *civil and criminal penalties, damages, fines, disgorgement, exclusion from*
8 *participation in governmental healthcare programs and the curtailment of our*
9 *operations, any of which could adversely impact our reputation and business*
10 *operations.*

To the extent our products are or become covered by any federal or state government
11 healthcare program, our operations and business practices may expose us to broadly
12 applicable fraud and abuse and other healthcare laws and regulations. These laws
13 may constrain the business or financial arrangements and relationships through
14 which we conduct our operations, including our sales and marketing practices,
15 consumer incentive and other promotional programs and other business practices.
16 Such laws include, without limitation:

17 * * *

- 18 • the U.S. federal false claims laws, including the False Claims Act, which can
19 be enforced through whistleblower actions, and civil monetary penalties
20 laws, which, among other things, impose criminal and civil penalties against
21 individuals or entities for knowingly presenting, or causing to be presented,
22 to the U.S. federal government, claims for payment or approval that are false
23 or fraudulent, knowingly making, using or causing to be made or used, a false
24 record or statement material to a false or fraudulent claim, or from knowingly
25 making a false statement to avoid, decrease or conceal an obligation to pay
26 money to the U.S. federal government. In addition, the government may
27 assert that a claim including items and services resulting from a violation of
28 the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the False Claims Act;

29 28. The above statements identified in ¶¶ 24-25, 27 were materially false and/or
30 misleading, and failed to disclose material adverse facts about the Company’s business, operations,
31 and prospects. Specifically, Defendants failed to disclose to investors: (1) that Eargo had improperly
32 sought reimbursements from certain third-party payors; (2) that the foregoing was reasonably likely
33 to lead to regulatory scrutiny; (3) that, as a result and because the reimbursements at issue involved
34 the Company’s largest third-party payor, Eargo’s financial results would be adversely impacted; and
35 (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business,
36 operations, and prospects were materially misleading and/or lacked a reasonable basis.

1 **Disclosures at the End of the Class Period**

2 29. On September 22, 2021, after the market closed, Eargo revealed that “it is the target
3 of a criminal investigation by the U.S. Department of Justice (the ‘DOJ’) related to insurance
4 reimbursement claims the Company has submitted on behalf of customers covered by federal
5 employee health plans.” Moreover, the DOJ is the “principal contact related to the subject matter of
6 the [ongoing] audit” of Eargo by an insurance company that is the Company’s largest third-party
7 payor. As a result of the foregoing, Eargo withdrew its full year financial guidance. Specifically, the
8 Company filed a Form 8-K with the SEC that stated, in relevant part:

9 On September 21, 2021, Eargo, Inc. (the “Company”) was informed that it is the
10 target of a criminal investigation by the U.S. Department of Justice (the “DOJ”) related to insurance reimbursement claims the Company has submitted on behalf of
11 its customers covered by federal employee health plans. The Company is cooperating
12 with the investigation. In addition, the Company intends to work with the government with the objective of validating the process to support any future claims
13 that the Company may submit for reimbursement.

14 As previously disclosed, the Company has been the subject of an ongoing claims
15 audit by an insurance company that is the Company’s largest third-party payor. The
16 Company has been informed by the insurance company that the DOJ is now the
17 principal contact related to the subject matter of the audit.

18 In light of this information, the Company is withdrawing its financial guidance for
19 the fiscal year ending December 31, 2021.

20 30. On this news, the Company’s share price fell \$14.81, or over 68%, to close at \$6.86
21 per share on September 23, 2021, on unusually heavy trading volume.

22 **CLASS ACTION ALLEGATIONS**

23 31. Plaintiff brings this action as a class action pursuant to Federal Rule of Civil
24 Procedure 23(a) and (b)(3) on behalf of a class, consisting of all persons and entities that purchased
25 or otherwise acquired Eargo securities between February 25, 2021 and September 22, 2021,
26 inclusive, and who were damaged thereby (the “Class”). Excluded from the Class are Defendants,
27 the officers and directors of the Company, at all relevant times, members of their immediate families
28 and their legal representatives, heirs, successors, or assigns, and any entity in which Defendants
29 have or had a controlling interest.

30 32. The members of the Class are so numerous that joinder of all members is
31 impracticable. Throughout the Class Period, Eargo’s shares actively traded on the NASDAQ.

1 While the exact number of Class members is unknown to Plaintiff at this time and can only be
2 ascertained through appropriate discovery, Plaintiff believes that there are at least hundreds or
3 thousands of members in the proposed Class. Millions of Eargo shares were traded publicly during
4 the Class Period on the NASDAQ. Record owners and other members of the Class may be identified
5 from records maintained by Eargo or its transfer agent and may be notified of the pendency of this
6 action by mail, using the form of notice similar to that customarily used in securities class actions.

7 33. Plaintiff's claims are typical of the claims of the members of the Class as all members
8 of the Class are similarly affected by Defendants' wrongful conduct in violation of federal law that
9 is complained of herein.

10 34. Plaintiff will fairly and adequately protect the interests of the members of the Class
11 and has retained counsel competent and experienced in class and securities litigation.

12 35. Common questions of law and fact exist as to all members of the Class and
13 predominate over any questions solely affecting individual members of the Class. Among the
14 questions of law and fact common to the Class are:

15 (a) whether the federal securities laws were violated by Defendants' acts as
16 alleged herein;

17 (b) whether statements made by Defendants to the investing public during the
18 Class Period omitted and/or misrepresented material facts about the business, operations, and
19 prospects of Eargo; and

20 (c) to what extent the members of the Class have sustained damages and the
21 proper measure of damages.

22 36. A class action is superior to all other available methods for the fair and efficient
23 adjudication of this controversy since joinder of all members is impracticable. Furthermore, as the
24 damages suffered by individual Class members may be relatively small, the expense and burden of
25 individual litigation makes it impossible for members of the Class to individually redress the wrongs
26 done to them. There will be no difficulty in the management of this action as a class action.

27
28

1 **UNDISCLOSED ADVERSE FACTS**

2 37. The market for Eargo’s securities was open, well-developed and efficient at all
3 relevant times. As a result of these materially false and/or misleading statements, and/or failures to
4 disclose, Eargo’s securities traded at artificially inflated prices during the Class Period. Plaintiff
5 and other members of the Class purchased or otherwise acquired Eargo’s securities relying upon the
6 integrity of the market price of the Company’s securities and market information relating to Eargo,
7 and have been damaged thereby.

8 38. During the Class Period, Defendants materially misled the investing public, thereby
9 inflating the price of Eargo’s securities, by publicly issuing false and/or misleading statements
10 and/or omitting to disclose material facts necessary to make Defendants’ statements, as set forth
11 herein, not false and/or misleading. The statements and omissions were materially false and/or
12 misleading because they failed to disclose material adverse information and/or misrepresented the
13 truth about Eargo’s business, operations, and prospects as alleged herein.

14 39. At all relevant times, the material misrepresentations and omissions particularized in
15 this Complaint directly or proximately caused or were a substantial contributing cause of the
16 damages sustained by Plaintiff and other members of the Class. As described herein, during the
17 Class Period, Defendants made or caused to be made a series of materially false and/or misleading
18 statements about Eargo’s financial well-being and prospects. These material misstatements and/or
19 omissions had the cause and effect of creating in the market an unrealistically positive assessment
20 of the Company and its financial well-being and prospects, thus causing the Company’s securities
21 to be overvalued and artificially inflated at all relevant times. Defendants’ materially false and/or
22 misleading statements during the Class Period resulted in Plaintiff and other members of the Class
23 purchasing the Company’s securities at artificially inflated prices, thus causing the damages
24 complained of herein when the truth was revealed.

25 **LOSS CAUSATION**

26 40. Defendants’ wrongful conduct, as alleged herein, directly and proximately caused
27 the economic loss suffered by Plaintiff and the Class.

1 Defendants made or caused to be made a series of materially false and/or misleading statements
2 about Eargo's business, prospects, and operations. These material misstatements and/or omissions
3 created an unrealistically positive assessment of Eargo and its business, operations, and prospects,
4 thus causing the price of the Company's securities to be artificially inflated at all relevant times, and
5 when disclosed, negatively affected the value of the Company shares. Defendants' materially false
6 and/or misleading statements during the Class Period resulted in Plaintiff and other members of the
7 Class purchasing the Company's securities at such artificially inflated prices, and each of them has
8 been damaged as a result.

9 45. At all relevant times, the market for Eargo's securities was an efficient market for
10 the following reasons, among others:

11 (a) Eargo shares met the requirements for listing, and was listed and actively
12 traded on the NASDAQ, a highly efficient and automated market;

13 (b) As a regulated issuer, Eargo filed periodic public reports with the SEC and/or
14 the NASDAQ;

15 (c) Eargo regularly communicated with public investors via established market
16 communication mechanisms, including through regular dissemination of press releases on the
17 national circuits of major newswire services and through other wide-ranging public disclosures,
18 such as communications with the financial press and other similar reporting services; and/or

19 (d) Eargo was followed by securities analysts employed by brokerage firms who
20 wrote reports about the Company, and these reports were distributed to the sales force and certain
21 customers of their respective brokerage firms. Each of these reports was publicly available and
22 entered the public marketplace.

23 46. As a result of the foregoing, the market for Eargo's securities promptly digested
24 current information regarding Eargo from all publicly available sources and reflected such
25 information in Eargo's share price. Under these circumstances, all purchasers of Eargo's securities
26 during the Class Period suffered similar injury through their purchase of Eargo's securities at
27 artificially inflated prices and a presumption of reliance applies.

28

1 **FIRST CLAIM**

2 **Violation of Section 10(b) of The Exchange Act and**
3 **Rule 10b-5 Promulgated Thereunder**
4 **Against All Defendants**

5 49. Plaintiff repeats and re-alleges each and every allegation contained above as if fully
6 set forth herein.

7 50. During the Class Period, Defendants carried out a plan, scheme and course of conduct
8 which was intended to and, throughout the Class Period, did: (i) deceive the investing public,
9 including Plaintiff and other Class members, as alleged herein; and (ii) cause Plaintiff and other
10 members of the Class to purchase Eargo's securities at artificially inflated prices. In furtherance of
11 this unlawful scheme, plan and course of conduct, Defendants, and each defendant, took the actions
12 set forth herein.

13 51. Defendants (i) employed devices, schemes, and artifices to defraud; (ii) made untrue
14 statements of material fact and/or omitted to state material facts necessary to make the statements
15 not misleading; and (iii) engaged in acts, practices, and a course of business which operated as a
16 fraud and deceit upon the purchasers of the Company's securities in an effort to maintain artificially
17 high market prices for Eargo's securities in violation of Section 10(b) of the Exchange Act and Rule
18 10b-5. All Defendants are sued either as primary participants in the wrongful and illegal conduct
19 charged herein or as controlling persons as alleged below.

20 52. Defendants, individually and in concert, directly and indirectly, by the use, means or
21 instrumentalities of interstate commerce and/or of the mails, engaged and participated in a
22 continuous course of conduct to conceal adverse material information about Eargo's financial well-
23 being and prospects, as specified herein.

24 53. Defendants employed devices, schemes and artifices to defraud, while in possession
25 of material adverse non-public information and engaged in acts, practices, and a course of conduct
26 as alleged herein in an effort to assure investors of Eargo's value and performance and continued
27 substantial growth, which included the making of, or the participation in the making of, untrue
28 statements of material facts and/or omitting to state material facts necessary in order to make the
statements made about Eargo and its business operations and future prospects in light of the

1 circumstances under which they were made, not misleading, as set forth more particularly herein,
2 and engaged in transactions, practices and a course of business which operated as a fraud and deceit
3 upon the purchasers of the Company's securities during the Class Period.

4 54. Each of the Individual Defendants' primary liability and controlling person liability
5 arises from the following facts: (i) the Individual Defendants were high-level executives and/or
6 directors at the Company during the Class Period and members of the Company's management team
7 or had control thereof; (ii) each of these defendants, by virtue of their responsibilities and activities
8 as a senior officer and/or director of the Company, was privy to and participated in the creation,
9 development and reporting of the Company's internal budgets, plans, projections and/or reports;
10 (iii) each of these defendants enjoyed significant personal contact and familiarity with the other
11 defendants and was advised of, and had access to, other members of the Company's management
12 team, internal reports and other data and information about the Company's finances, operations, and
13 sales at all relevant times; and (iv) each of these defendants was aware of the Company's
14 dissemination of information to the investing public which they knew and/or recklessly disregarded
15 was materially false and misleading.

16 55. Defendants had actual knowledge of the misrepresentations and/or omissions of
17 material facts set forth herein, or acted with reckless disregard for the truth in that they failed to
18 ascertain and to disclose such facts, even though such facts were available to them. Such defendants'
19 material misrepresentations and/or omissions were done knowingly or recklessly and for the purpose
20 and effect of concealing Eargo's financial well-being and prospects from the investing public and
21 supporting the artificially inflated price of its securities. As demonstrated by Defendants'
22 overstatements and/or misstatements of the Company's business, operations, financial well-being,
23 and prospects throughout the Class Period, Defendants, if they did not have actual knowledge of the
24 misrepresentations and/or omissions alleged, were reckless in failing to obtain such knowledge by
25 deliberately refraining from taking those steps necessary to discover whether those statements were
26 false or misleading.

27 56. As a result of the dissemination of the materially false and/or misleading information
28 and/or failure to disclose material facts, as set forth above, the market price of Eargo's securities

1 was artificially inflated during the Class Period. In ignorance of the fact that market prices of the
2 Company's securities were artificially inflated, and relying directly or indirectly on the false and
3 misleading statements made by Defendants, or upon the integrity of the market in which the
4 securities trades, and/or in the absence of material adverse information that was known to or
5 recklessly disregarded by Defendants, but not disclosed in public statements by Defendants during
6 the Class Period, Plaintiff and the other members of the Class acquired Eargo's securities during the
7 Class Period at artificially high prices and were damaged thereby.

8 57. At the time of said misrepresentations and/or omissions, Plaintiff and other members
9 of the Class were ignorant of their falsity, and believed them to be true. Had Plaintiff and the other
10 members of the Class and the marketplace known the truth regarding the problems that Eargo was
11 experiencing, which were not disclosed by Defendants, Plaintiff and other members of the Class
12 would not have purchased or otherwise acquired their Eargo securities, or, if they had acquired such
13 securities during the Class Period, they would not have done so at the artificially inflated prices
14 which they paid.

15 58. By virtue of the foregoing, Defendants violated Section 10(b) of the Exchange Act
16 and Rule 10b-5 promulgated thereunder.

17 59. As a direct and proximate result of Defendants' wrongful conduct, Plaintiff and the
18 other members of the Class suffered damages in connection with their respective purchases and
19 sales of the Company's securities during the Class Period.

20 **SECOND CLAIM**

21 **Violation of Section 20(a) of The Exchange Act**
22 **Against the Individual Defendants**

23 60. Plaintiff repeats and re-alleges each and every allegation contained above as if fully
24 set forth herein.

25 61. Individual Defendants acted as controlling persons of Eargo within the meaning of
26 Section 20(a) of the Exchange Act as alleged herein. By virtue of their high-level positions and their
27 ownership and contractual rights, participation in, and/or awareness of the Company's operations
28 and intimate knowledge of the false financial statements filed by the Company with the SEC and

JURY TRIAL DEMANDED

Plaintiff hereby demands a trial by jury.

DATED: October 6, 2021

GLANCY PRONGAY & MURRAY LLP

By: s/ Pavithra Rajesh

Robert V. Prongay

Charles Linehan

Pavithra Rajesh

1925 Century Park East, Suite 2100

Los Angeles, California 90067

Telephone: (310) 201-9150

Facsimile: (310) 201-9160

Email: info@glancylaw.com

Counsel for Plaintiff Joseph Fazio

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**SWORN CERTIFICATION OF PLAINTIFF
EARGO, INC. (EAR) SECURITIES LITIGATION**

I, Joseph Fazio, certify that:

1. I have reviewed the Complaint and authorize its filing and/or the filing of a Lead Plaintiff motion on my behalf.
2. I did not purchase the Eargo, Inc. securities that are the subject of this action at the direction of plaintiff's counsel or in order to participate in any private action arising under this title.
3. I am willing to serve as a representative party on behalf of a class and will testify at deposition and trial, if necessary.
4. My transactions in Eargo, Inc. securities during the Class Period set forth in the Complaint are as follows:

(See attached transactions)
5. I have not sought to serve, nor served, as a representative party on behalf of a class under this title during the last three years, except for the following:
6. I will not accept any payment for serving as a representative party, except to receive my pro rata share of any recovery or as ordered or approved by the court, including the award to a representative plaintiff of reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

I declare under penalty of perjury that the foregoing are true and correct statements.

9/25/2021

Date



Joseph Fazio

Joseph Fazio's Transactions in Eargo, Inc. (EAR)

Date	Transaction Type	Quantity	Unit Price
6/25/2021	Bought	100	\$37.8564
7/9/2021	Bought	150	\$31.8000
7/9/2021	Bought	100	\$31.2800
7/9/2021	Bought	100	\$32.9800
7/9/2021	Bought	100	\$34.0000
7/9/2021	Sold	-300	\$34.9000
8/12/2021	Bought	10	\$31.9200
8/12/2021	Bought	10	\$31.7500
8/13/2021	Bought	50	\$26.3000
8/13/2021	Bought	5	\$25.1795
8/13/2021	Bought	50	\$30.0000
8/16/2021	Bought	100	\$24.5900
8/17/2021	Bought	10	\$24.0950
8/17/2021	Bought	50	\$24.7200
8/18/2021	Bought	50	\$23.9000
8/19/2021	Bought	25	\$21.4750
8/19/2021	Bought	5	\$22.2100
8/19/2021	Bought	10	\$22.6900
8/20/2021	Bought	5	\$21.5400
8/25/2021	Bought	50	\$21.5000
8/30/2021	Bought	10	\$21.2000
8/31/2021	Bought	15	\$20.0500
8/31/2021	Bought	10	\$19.9000
9/1/2021	Bought	5	\$20.4494
9/2/2021	Bought	100	\$20.4000
9/7/2021	Bought	10	\$20.7657
9/10/2021	Bought	70	\$20.5000
9/13/2021	Bought	100	\$20.6470
9/16/2021	Bought	50	\$21.4630
9/20/2021	Bought	50	\$20.8198
9/22/2021	Bought	50	\$21.7050